Get the Stockscreener App
28.38
2.00%
-0.58
Mineralys Therapeutics Inc stock is traded at $28.38, with a volume of 727.68K.
It is down -2.00% in the last 24 hours and up +19.44% over the past month.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
See More
Previous Close:
$28.96
Open:
$28.86
24h Volume:
727.68K
Relative Volume:
0.48
Market Cap:
$2.50B
Revenue:
-
Net Income/Loss:
$-151.78M
P/E Ratio:
-13.78
EPS:
-2.0595
Net Cash Flow:
$-136.42M
1W Performance:
+2.49%
1M Performance:
+19.44%
6M Performance:
-14.95%
1Y Performance:
+93.85%
1-Day Range:
$27.69
$28.90
1-Week Range:
$27.01
$31.11
52-Week Range:
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
28.38 | 2.50B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | TD Cowen | Buy |
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys Therapeutics CMO Rodman sells $65,781 in stock By Investing.com - Investing.com India
Form 4 Mineralys Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Mineralys Therapeutics CMO Rodman sells $65,781 in stock - Investing.com UK
Mineralys Therapeutics (MLYS) CMO sells 2,171 shares after option exercise - Stock Titan
Mineralys (MLYS) reports 2,171-share exercise; Rodman sales listed - Stock Titan
Responsive Playbooks and the MLYS Inflection - Stock Traders Daily
Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative? - simplywall.st
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger - Yahoo Finance
Have Insiders Sold Mineralys Therapeutics Shares Recently? - simplywall.st
Have Mineralys Therapeutics Insiders Been Selling Stock? - Moomoo
Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential? - Insider Monkey
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) - 富途牛牛
Mineralys Therapeutics Insider Sold Shares Worth $2,696,322, According to a Recent SEC Filing - marketscreener.com
Mineralys Therapeutics Insider Sold Shares Worth $1,960,601, According to a Recent SEC Filing - marketscreener.com
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
Insider Sell: CEO Jon Congleton Sells 75,000 Shares of Mineralys Therapeutics Inc (MLYS) - GuruFocus
Form 4 Mineralys Therapeutics Inc For: 30 June By Investing.com - Investing.com Australia
Mineralys Therapeutics CEO Jon Congleton sells $1.96m in stock - Investing.com
Mineralys Therapeutics CCO Eric Warren sells $2.7m in shares By Investing.com - Investing.com Australia
Mineralys Therapeutics CCO Eric Warren sells $2.7m in shares - Investing.com UK
Mineralys Therapeutics CEO Jon Congleton sells $1.96m in stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (MLYS) CEO sells 75K shares under Rule 10b5-1 plan - Stock Titan
Mineralys (NASDAQ: MLYS) CCO sells shares after option exercise - Stock Titan
Mineralys Therapeutics (MLYS) Form 144 lists 90,730 shares sold and RSU vesting - Stock Titan
Form 144 Mineralys Therapeutics For: 29 June By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (NASDAQ: MLYS) flagged sale of 104,124 shares via cashless exercise - Stock Titan
Mineralys Therapeutics, Inc.(NasdaqGS:MLYS) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Mineralys Therapeutics, Inc.(NasdaqGS:MLYS) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell Microcap Index - marketscreener.com
Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 3000E Index - marketscreener.com
Enterprise value to EBITDA forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Price to earnings forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Price to sales forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Price to book forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision - AOL.com
MLYS Forecast — Price Target — Prediction for 2027 - TradingView
Mineralys Therapeutics, Inc. Actuals & Estimates (NASDAQ:MLYS) - TradingView
Mineralys Therapeutics, Inc. Actuals & Estimates (BOATS:MLYS) - TradingView
Mineralys Therapeutics Inc (MLYS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mineralys Therapeutics (MLYS) Edges Higher as Shares Hold Above Key SupportSign of Strength - Město Břeclav
Mineralys Therapeutics Inc (MLYS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mineralys Therapeutics Inc (MLYS) Institutional Confidence - TradingKey
Mineralys: Limited Differentiation Makes Lorundrostat A Weak Competitor - Seeking Alpha
Mineralys Therapeutics Inc (MLYS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mineralys Therapeutics Inc (MLYS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mineralys Therapeutics director Karydas sells $75,000 in stock By Investing.com - Investing.com India
Mineralys Therapeutics CMO Rodman sells $350,086 in stock By Investing.com - Investing.com India
Mineralys Therapeutics (MLYS) CMO sells 14,474 shares, exercises options - Stock Titan
Director at Mineralys Therapeutics (MLYS) trades 3,000 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):